Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Golidocitinib in Healthy Men
NCT04225208Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Percentage of radioactive dose recovered in urine and faeces and total percentage up to 57 days and Provide samples for subsequent studies up to 57 days. Started Jan 2020; status: completed.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04225208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225208.